JP2019517815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517815A5 JP2019517815A5 JP2018566257A JP2018566257A JP2019517815A5 JP 2019517815 A5 JP2019517815 A5 JP 2019517815A5 JP 2018566257 A JP2018566257 A JP 2018566257A JP 2018566257 A JP2018566257 A JP 2018566257A JP 2019517815 A5 JP2019517815 A5 JP 2019517815A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- vector according
- cells
- nkg2d ligand
- mirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 47
- 210000004027 cell Anatomy 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- 239000003446 ligand Substances 0.000 claims 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 11
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 108091070501 miRNA Proteins 0.000 claims 8
- 239000002679 microRNA Substances 0.000 claims 8
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 claims 5
- 102100040011 UL16-binding protein 3 Human genes 0.000 claims 5
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 claims 4
- 108700019146 Transgenes Proteins 0.000 claims 4
- 102100040012 UL16-binding protein 1 Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 claims 3
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 claims 3
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 claims 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 3
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 claims 3
- 241000700584 Simplexvirus Species 0.000 claims 3
- 102100040010 UL-16 binding protein 5 Human genes 0.000 claims 3
- 102100039989 UL16-binding protein 2 Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 230000000174 oncolytic effect Effects 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 claims 2
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims 2
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims 2
- 101150090364 ICP0 gene Proteins 0.000 claims 2
- 101150027427 ICP4 gene Proteins 0.000 claims 2
- 101100148566 Mus musculus S1pr3 gene Proteins 0.000 claims 2
- 101100172613 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERG10 gene Proteins 0.000 claims 2
- 102100040013 UL16-binding protein 6 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 101710130522 mRNA export factor Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091056924 miR-124 stem-loop Proteins 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 108091007780 MiR-122 Proteins 0.000 claims 1
- 108091027966 Mir-137 Proteins 0.000 claims 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 101150042088 UL16 gene Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003197 gene knockdown Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108091051828 miR-122 stem-loop Proteins 0.000 claims 1
- 108091070946 miR-128 stem-loop Proteins 0.000 claims 1
- 108091047177 miR-199 stem-loop Proteins 0.000 claims 1
- 108091031898 miR-199-5 stem-loop Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350095P | 2016-06-14 | 2016-06-14 | |
| US62/350,095 | 2016-06-14 | ||
| PCT/US2017/037531 WO2017218689A1 (en) | 2016-06-14 | 2017-06-14 | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517815A JP2019517815A (ja) | 2019-06-27 |
| JP2019517815A5 true JP2019517815A5 (enExample) | 2020-07-27 |
| JP7184337B2 JP7184337B2 (ja) | 2022-12-06 |
Family
ID=60664263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566257A Active JP7184337B2 (ja) | 2016-06-14 | 2017-06-14 | 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11427625B2 (enExample) |
| EP (1) | EP3468588A4 (enExample) |
| JP (1) | JP7184337B2 (enExample) |
| CN (1) | CN109475613B (enExample) |
| AU (1) | AU2017285213B2 (enExample) |
| CA (1) | CA3027857C (enExample) |
| MX (1) | MX2018015542A (enExample) |
| NZ (1) | NZ749586A (enExample) |
| WO (1) | WO2017218689A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000691XA (en) | 2017-07-26 | 2020-02-27 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| GB2578394A (en) | 2017-08-07 | 2020-05-06 | Univ California | Platform for generating safe cell therapeutics |
| EP3833765B1 (en) * | 2017-08-09 | 2026-01-14 | Ohio State Innovation Foundation | Oncolytic virus carrying e-cadherin and uses thereof |
| EP3781188A4 (en) * | 2018-04-13 | 2022-03-02 | 2seventy bio, Inc. | ADOPTIVE CELL THERAPY |
| EP3874041A1 (en) * | 2018-11-01 | 2021-09-08 | Onconetics Pharmaceuticals, Inc. | Multi-component vector systems, methods of making, and uses thereof |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| IL307223A (en) * | 2021-04-08 | 2023-11-01 | Immvira Biopharmaceuticals Co Ltd | Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen |
| CN118389408B (zh) * | 2024-06-26 | 2024-11-29 | 淇嘉科技(苏州)有限公司 | 炎症性肠病及纤维化体外精准模拟方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2315251A1 (en) | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
| JP2005523681A (ja) | 2001-10-04 | 2005-08-11 | イミュネックス・コーポレーション | Ｕｌ１６結合タンパク質４ |
| US20150165065A1 (en) * | 2009-12-31 | 2015-06-18 | Avidbiotics Corp. | Non-natural mic proteins |
| WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| EP3063279B1 (en) | 2013-10-28 | 2020-01-01 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Oncolytic hsv vector |
-
2017
- 2017-06-14 EP EP17814031.5A patent/EP3468588A4/en active Pending
- 2017-06-14 US US16/309,862 patent/US11427625B2/en active Active
- 2017-06-14 NZ NZ749586A patent/NZ749586A/en unknown
- 2017-06-14 CA CA3027857A patent/CA3027857C/en active Active
- 2017-06-14 WO PCT/US2017/037531 patent/WO2017218689A1/en not_active Ceased
- 2017-06-14 MX MX2018015542A patent/MX2018015542A/es unknown
- 2017-06-14 JP JP2018566257A patent/JP7184337B2/ja active Active
- 2017-06-14 AU AU2017285213A patent/AU2017285213B2/en active Active
- 2017-06-14 CN CN201780036512.5A patent/CN109475613B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517815A5 (enExample) | ||
| EP2986311B1 (en) | Enhanced adoptive cell therapy | |
| ES2385251B1 (es) | Adenovirus oncolíticos para el tratamiento del cáncer. | |
| ES2367227T3 (es) | Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer. | |
| US20200171110A1 (en) | Hsv vector with reduced neurotoxicity | |
| RU2016120618A (ru) | Онколитический hsv-вектор | |
| Ruiz et al. | MicroRNA-detargeted mengovirus for oncolytic virotherapy | |
| CN109475613B (zh) | 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达 | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| Hulou et al. | Experimental therapies: gene therapies and oncolytic viruses | |
| US20240026380A1 (en) | Microrna-based compositions and methods used in disease treatment | |
| Parsel et al. | Nucleic acid targeting: towards personalized therapy for head and neck cancer | |
| JP5645044B2 (ja) | 遺伝子発現制御機構を含む新規Ａｄベクター | |
| Chouljenko et al. | Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 | |
| Jiang et al. | Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma | |
| Rezaei et al. | Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses | |
| US7371570B2 (en) | Cell-specific adenovirus vector comprising EBV-specific promoter | |
| Post | Genetics of otitis media | |
| Zhu et al. | Growth and expression of rat bone marrow mesenchymal stem cells modified by nerve growth factor in diabetic rat bladders | |
| WO2023142040A1 (en) | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors | |
| Hua et al. | Progression of oncolytic virus in liver cancer treatment | |
| CN112823209A (zh) | 使用编码高度紧凑的多输入逻辑门的核酸载体治疗疾病的方法 | |
| Garcia-Aragoncillo et al. | Design of virotherapy for effective tumor treatment | |
| Gil | Design and Characterization of A CXCR4-Retargeted and Strailarmed Oncolytic HSV-1 to Attack Glioblastoma Stem-Like Cells (GSCs) | |
| Singh | Journal of Yeungnam Medical Science |